The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| 4D MOLECULAR THERAPEUTICS IN | COM | 35104E100 | 29 | 3,573 | SH | SOLE | 3,573 | 0 | 0 | ||
| AMRYT PHARMA PLC | SPONSORED ADS | 03217L106 | 13,833 | 1,998,993 | SH | SOLE | 1,998,993 | 0 | 0 | ||
| ARGENX SE | SPONSORED ADR | 04016X101 | 8,473 | 24,000 | SH | SOLE | 24,000 | 0 | 0 | ||
| ARROWHEAD PHARMACEUTICALS IN | COM | 04280A100 | 40,272 | 1,218,515 | SH | SOLE | 1,218,515 | 0 | 0 | ||
| ARVINAS INC | COM | 04335A105 | 29,886 | 671,745 | SH | SOLE | 671,745 | 0 | 0 | ||
| BLUEPRINT MEDICINES CORP | COM | 09627Y109 | 34,544 | 524,268 | SH | SOLE | 524,268 | 0 | 0 | ||
| GENMAB A/S | SPONSORED ADS | 372303206 | 7,867 | 244,848 | SH | SOLE | 244,848 | 0 | 0 | ||
| KYMERA THERAPEUTICS INC | COM | 501575104 | 7,189 | 330,246 | SH | SOLE | 330,246 | 0 | 0 | ||
| MERUS N V | COM | N5749R100 | 30,187 | 1,507,109 | SH | SOLE | 1,507,109 | 0 | 0 | ||
| PIERIS PHARMACEUTICALS INC | COM | 720795103 | 4,642 | 4,036,280 | SH | SOLE | 4,036,280 | 0 | 0 | ||
| REGENXBIO INC | COM | 75901B107 | 25,576 | 967,684 | SH | SOLE | 967,684 | 0 | 0 | ||
| S&P BIOTECH ETF TR | UNIT | 78464A870 | 39,660 | 500,000 | SH | Put | SOLE | 0 | 0 | 500,000 | |
| SILENCE THERAPEUTICS PLC | ADS | 82686Q101 | 12,675 | 1,263,125 | SH | SOLE | 1,263,125 | 0 | 0 | ||
| SPERO THERAPEUTICS INC | COM | 84833T103 | 6,806 | 3,403,210 | SH | SOLE | 3,403,210 | 0 | 0 | ||
| UNIQURE NV | SHS | N90064101 | 15,786 | 841,471 | SH | SOLE | 841,471 | 0 | 0 | ||